Literature DB >> 19941739

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.

Thomas Stauffer Larsen1, Michael Boe Møller, Karin de Stricker, Peter Nørgaard, Jan Samuelsson, Claus Marcher, Morten T Andersen, Ole Weis Bjerrum, Hans Carl Hasselbalch.   

Abstract

Polycythemia vera (PV) is characterized by the presence of the JAK2V617F mutation in virtually all patients. Several studies have shown that the JAK2V617F mutational load decreases during treatment with alpha-interferon 2. We report on molecular and histomorphological bone marrow responses in seven PV patients with profound molecular responses during and after long-term treatment with alpha-interferon 2b. All patients obtained a major molecular response (MMR). Subsequently all patients discontinued alpha-interferon and sustained complete hematological remission with a follow-up period of median 10 months (range 4-30 months). Complete normalization of the bone marrow was seen in three of five patients. Long term treatment with IFN2b is able to induce 'minimal residual disease' with very low JAK2 V617F allele burden and may induce profound, and in some patients total, regression of histomorphological bone marrow features of PV. Finally, hematological remissions and major molecular responses can be sustained after discontinuation of long-term treatment with IFN2b.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941739     DOI: 10.1179/102453309X12473408860587

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  23 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 2.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

3.  2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.

Authors:  Jan Jacques Michiels; Mihaela Tevet; Adrian Trifa; Emilia Niculescu-Mizil; Anca Lupu; Ana Maria Vladareanu; Horia Bumbea; Anca Ilea; Camelia Dobrea; Daniela Georgescu; Oana Patrinoiu; Mihaela Popescu; Meilin Murat; Cornel Dragan; Felicia Mihai; Sabina Zurac; Silvana Angelescu; Anamaria Iova; Alina Popa; Rodica Gogulescu; Violeta Popov
Journal:  Maedica (Bucur)       Date:  2016-03

4.  Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.

Authors:  Elizabeth Margolskee; Spencer Krichevsky; Attilio Orazi; Richard T Silver
Journal:  Haematologica       Date:  2016-11-03       Impact factor: 9.941

5.  Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.

Authors:  Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Nikolai Podoltsev; Robert T Williams; Raajit K Rampal; Martin S Tallman; Amer M Zeidan; Maximilian Stahl
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-28

Review 6.  Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.

Authors:  Charles Elliott Foucar; Brady Lee Stein
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 7.  Novel and emerging therapies for the treatment of polycythemia vera.

Authors:  Srdan Verstovsek; Rami S Komrokji
Journal:  Expert Rev Hematol       Date:  2014-10-29       Impact factor: 2.929

8.  Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Authors:  Vibe Skov; Mads Thomassen; Lasse Kjær; Christina Ellervik; Morten Kranker Larsen; Trine Alma Knudsen; Torben A Kruse; Hans C Hasselbalch
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

9.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

Review 10.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.